1/69
Comprehensive practice flashcards covering GCP Investigator Responsibilities I, including qualifications, adequate resources, team training, protocol compliance, deviations, premature termination, medical care, safety reporting, randomization, and CRF data recording rules.
What are the primary site-level stakeholders in a clinical trial?
The Principal Investigator (PI), Co-Investigator (Co-I), Clinical Research Coordinator (CRC), and the study team (such as the research pharmacist, research nurse, and technician).
Which study stakeholder serves as the main communication point to the Ethics Committee (EC) or Institutional Review Board (IRB)?
The study site team, led by the Principal Investigator (PI).
Who are the primary sponsor-level stakeholders involved in a clinical trial?
The pharmaceutical company or contract research organization (CRO), Clinical Research Associate (CRA), Clinical Trials Assistant/executive (CTA), Biostatistician, and the sponsor study team (scientific officer, pharmacovigilance, data management, central laboratory, etc.).
Which entity serves as the main communication point to the Health Sciences Authority (HSA)?
The sponsor.
Which regulatory bodies and oversight committees oversee clinical trials?
The Ethics Committee (EC) / Institutional Review Board (IRB) and Regulatory Authorities (RA) such as the HSA, FDA, and EMA.
What does the abbreviation CRA stand for in clinical trials?
Clinical Research Associate.
What does the abbreviation CTA stand for in a sponsor study team?
Clinical Trials Assistant or Clinical Trials Executive.
What does the abbreviation CRO stand for in clinical research?
Contract Research Organization.
According to ICH GCP 4.1.1, how must an investigator be qualified to assume responsibility for a clinical trial?
The investigator should be qualified by education, training, and experience to assume responsibility for the proper conduct of the trial.
How should an investigator provide evidence of their qualifications according to ICH GCP?
By providing an up-to-date curriculum vitae (CV) and/or other relevant documentation requested by the sponsor, EC/IRB, or regulatory authority.
What fundamental guidelines and requirements must an investigator be aware of and comply with?
Good Clinical Practice (GCP) and all applicable regulatory requirements.
What are the four document sources where information regarding the investigational product (IP) can be found?
What does the abbreviation IB stand for in clinical trials?
Investigator's Brochure.
What does the abbreviation PIB stand for?
Product Information Brochure.
How should an investigator demonstrate adequate recruitment potential for a trial?
The investigator should be able to demonstrate (e.g., based on retrospective data) a potential for recruiting the required number of suitable trial participants within the agreed recruitment period.
What is the investigator's responsibility regarding time commitment under adequate resources?
The investigator should have sufficient time to properly conduct and complete the trial within the agreed trial period.
What personnel and facility requirements must an investigator ensure for the foreseen duration of the trial?
An adequate number of qualified staff and adequate facilities to conduct the trial properly and safely.
What information must the investigator provide to all persons assisting with the trial to ensure team well-being and competence?
Ensure that all assisting staff are adequately informed about the protocol, the investigational product(s), and their assigned trial activities.
What is the requirement for trial-related training provided to staff assisting with the trial?
The training should correspond to what is necessary to enable them to fulfil their delegated trial activities that go beyond their usual training and experience.
What must the investigator or institution verify if retaining an outside party or individual to perform trial-related duties?
Ensure that the individual or party is qualified to perform those trial-related duties and functions.
What procedures must an investigator implement when third parties perform trial-related duties?
Implement procedures to ensure the integrity of the trial-related duties and functions performed and any data generated.
What document must an investigator maintain regarding trial task allocation (site delegation)?
A list of appropriately qualified persons to whom the investigator has delegated significant trial-related duties (Delegation of Authority Log).
What oversight activities must an investigator agree to permit at the trial site?
Monitoring and auditing by the sponsor, as well as inspections by the Ethics Committee (EC) and Regulatory Authority (RA).
Which documents require written and dated approval from the RA and EC prior to trial initiation?
The trial protocol, written informed consent form, consent form updates, trial participant recruitment procedures (e.g., advertisements), and any other written information provided to participants.
What document must an investigator submit to the EC regarding drug safety and pharmacological data as part of the initial application?
A current copy of the Investigator's Brochure (IB) or Product Information Brochure (PIB).
What must the investigator do if the Investigator's Brochure (IB) is updated during the trial?
The investigator should supply a copy of the updated IB to both the Ethics Committee (EC) and the Regulatory Authority (RA).
What participant information updates must the investigator provide to the RA and EC during the trial?
Any updates to participant information, such as revised informed consent documents.
What reports and trial changes must the investigator submit to the RA and EC during the course of the trial?
Summaries of the trial status and any changes significantly affecting the conduct of the trial and/or increasing risk to participants.
How does the investigator confirm formal agreement with the sponsor to follow the trial protocol?
By signing the protocol or an alternative contract.
What are the three pillars of compliance that an investigator must adhere to when conducting a trial?
The trial protocol, Good Clinical Practice (GCP), and applicable regulatory requirements.
What actions must an investigator take when a protocol deviation (PD) occurs?
Document all protocol deviations, review and explain the deviations, and implement appropriate measures to prevent a recurrence.
Must protocol deviations identified by the sponsor during monitoring visits be documented by the investigator?
Yes, all protocol deviations, including those identified by the sponsor during monitoring, must be documented.
Under what condition is an investigator permitted to implement a deviation from the protocol without prior approval?
Only where necessary to eliminate an immediate hazard(s) to trial participants.
What three actions must an investigator take after implementing a deviation to eliminate an immediate hazard without prior approval?
What must an investigator do if a participant misses a scheduled visit resulting in a protocol deviation?
Document the protocol deviation, review and explain the deviation, and implement appropriate measures to prevent recurrence.
What are TWO exceptional situations where protocol deviations or changes may be implemented without prior EC/RA and sponsor approval?
What must the investigator do for trial participants if a trial is prematurely terminated or suspended for any reason?
Promptly inform the trial participants and ensure appropriate therapy and follow-up for them.
Who must be informed if a clinical trial is prematurely terminated or suspended by the investigator or sponsor?
The institution, IRB/IEC, and regulatory authorities must be promptly informed with a detailed written explanation of the reasons.
Who must the investigator promptly inform if the IRB terminates or suspends a trial?
The institution and the sponsor.
What medical professionals registered to practice are qualified to hold responsibility for trial-related medical care and decisions?
A qualified physician, a qualified dentist, or qualified healthcare professionals (in accordance with local regulatory requirements) serving as PI or Co-I.
What medical care responsibility does an investigator have regarding adverse events (AEs)?
Ensure that adequate medical care is provided to a trial participant for any adverse events, including clinically significant laboratory values, related to the trial.
What is the investigator's obligation when becoming aware of an intercurrent illness in a participant?
Inform the trial participant when medical care is needed for intercurrent illness(es) of which the investigator becomes aware.
What steps must an investigator take when retaining an outside facility to perform study assessments?
Ensure the facility is adequate (e.g., verifying certifications or licenses) and institute procedures ensuring data integrity, authenticity, and accuracy.
What level of access to medical care must an investigator provide if a study drug has potentially fatal toxicity?
The investigator should be readily available by phone or other electronic communication 24 hours a day and in reasonably close proximity to study participants.
How should trial participants be instructed regarding emergency medical contact with trial staff?
Participants should be clearly educated on when and how to seek contact, and be provided with phone numbers, email addresses, and other contact information in writing.
What must an investigator arrange regarding participant medical care during periods of planned absence or unavailability?
Delegate responsibility for medical care to a specific qualified physician who will be readily available to trial participants during that time.
Under what condition is it recommended that the investigator inform a participant's primary physician of trial participation?
It is recommended to inform the primary physician with the agreement of the trial participant.
In an emergency, who is permitted to provide treatment to a participant if the investigator is unavailable?
Any doctor may treat a trial participant in the absence of the investigator if it is in the interest of the participant.
What are the three core principles summarizing an investigator's medical care duties?
How should critical adverse events or laboratory abnormalities be reported to the sponsor?
They should be reported according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
Are unfavourable medical events occurring before investigational product administration (e.g., during screening) reportable?
Yes, they should be considered and reported to the sponsor if required by the protocol.
What is the general reporting timeline for Serious Adverse Events (SAEs) to the sponsor?
All SAEs should be reported immediately to the sponsor, followed promptly by detailed, written reports.
Which Serious Adverse Events (SAEs) are exempt from immediate reporting to the sponsor?
Those SAEs that the protocol or other document (such as the Investigator's Brochure) identifies as not needing immediate reporting.
What additional documentation must the investigator supply to the sponsor and IRB/IEC in the event of a participant's death?
Any requested additional information, such as autopsy reports and terminal medical reports.
Can an investigator delegate safety reporting duties, and who retains ultimate legal and ethical responsibility?
The investigator may delegate safety reporting activities to qualified site staff, but retains overall responsibility for participant safety and reporting compliance.
According to randomization guidelines, when is an investigator allowed to break a study randomization code?
The code must be broken only in accordance with the protocol.
What must an investigator do if premature unblinding occurs in a blinded clinical trial?
The investigator should promptly document and explain any premature unblinding to the sponsor.
What are two examples of reasons for premature unblinding in a blinded clinical trial?
Accidental unblinding and unblinding necessitated by a serious adverse event (SAE).
If a code or cipher is used to label test material, to whom must the key be disclosed and accessible?
The key must be made known to the sponsor and be readily accessible to authorized healthcare personnel or the investigator in an emergency.
Name TWO documents maintained by the investigator that contain the names and particulars of trial personnel.
What FOUR data quality characteristics must an investigator ensure for data reported in CRFs to the sponsor?
The accuracy, completeness, legibility, and timeliness of the data.
What is the requirement when source data reported on a CRF is derived from source records?
It should be consistent with the source records, or any discrepancies/differences should be explained.
What THREE requirements must be fulfilled when making any change or correction to a CRF?
Any change or correction should be dated, initialed, and explained (e.g., via an audit trail).
What strict rule applies to the original entry when correcting data on a CRF?
The correction should not obscure the original entry.
What does the abbreviation CRF stand for in clinical trial documentation?
Case Report Form.
What is the primary function of an audit trail in clinical trial electronic data reporting?
To maintain a secure, computer-generated, time-stamped record of all entries, changes, and deletions without obscuring original data.
In clinical research, what is meant by an "intercurrent illness"?
An illness or medical condition that occurs during the course of the trial that is independent of or concurrent with the main condition under evaluation.